Women who use Depo-Provera face a higher risk of developing a slow-growing brain tumor, according to a new study that comes as the contraceptive’s maker, Pfizer, faces hundreds of lawsuits claiming that it was aware of the potential risks. Depo-Provera — the brand name for depot medroxyprogesterone acetate (DMPA) — contains the synthetic progestin hormone, which stops the ovaries from releasing an egg to prevent pregnancy. The injections, used by roughly 1 in 4 sexually active US women at some